Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05905705 · ClinicalTrials.gov registry record
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
A clinical trial of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05905705: Recruiting study of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
NCT05905705 is a study of Treatment-Resistant Depression that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 50 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05905705, a study of Treatment-Resistant Depression, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
Primary Outcome
Total power of EEG slow waves per minute present during N2/N3 sleep
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Electroencephalography (EEG)
- DIAGNOSTIC_TEST Quantitative Measurements of Sleep Microstructure
Study Locations (1)
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2027-07-31 |
What NCT05905705 shows while recruiting
NCT05905705 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Electroencephalography (EEG) is the first listed.
NCT05905705 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05905705 about?
NCT05905705 is a clinical study titled "Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy". Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
What is the current status of trial NCT05905705?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-03-07. Estimated completion is 2027-07-31.
What conditions does trial NCT05905705 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT05905705?
The interventions under investigation include: Electroencephalography (EEG) (DIAGNOSTIC_TEST), Quantitative Measurements of Sleep Microstructure (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05905705?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05905705 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05905705's enrollment target sits among peer trials
50 28th of 54 higher than 26 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
RECRUITING
-
DBS for Depression
RECRUITING · Phase 1
-
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
RECRUITING · NA
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI